Meloxicam
Meloxicam (Mobic) is a once-daily prescription nonsteroidal anti-inflammatory drug (NSAID) for osteoarthritis and rheumatoid arthritis. The liver enzyme CYP2C9 does most of its metabolism, and because meloxicam already lasts most of a day, slow clearance keeps levels high for longer than with shorter-acting NSAIDs. The Clinical Pharmacogenetics Implementation Consortium (CPIC) advises prescribers to start intermediate metabolizers with an activity score of 1 at half the lowest dose or to choose another drug, and to choose another drug for poor metabolizers.
| Brand names | Mobic (US brand discontinued; generic tablets). Meloxicam is also in Symbravo (with rizatriptan), Zynrelef (with bupivacaine) and the injections Xifyrm and Qamzova. |
|---|---|
| Used for | Tablets: osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis in children who weigh at least 60 kg. Symbravo: acute migraine. Zynrelef: pain for up to 72 hours after certain operations. Injections: moderate to severe pain in adults. |
| Genes | CYP2C9 |
| Guidance | CPIC guideline (2020), level A; FDA Table of Pharmacogenetic Associations, Section 1; poor-metabolizer advice in the Xifyrm, Qamzova, Zynrelef and Symbravo labels (Section 8.8) |
How meloxicam works
Meloxicam relieves pain and inflammation by blocking the cyclooxygenase (COX) enzymes that make prostaglandins. CPIC groups it with celecoxib and diclofenac as COX-2 selective [1]. The tablets come in 7.5 mg and 15 mg. For osteoarthritis and rheumatoid arthritis, the label's starting dose is 7.5 mg once a day, which some people raise to 15 mg, the maximum daily dose of oral meloxicam [2].
Meloxicam is absorbed slowly, and a second peak in the blood 12 to 14 hours after a dose suggests that some of it is recycled through the bile. Its half-life is about 20 hours, and levels reach a steady state by day 5. Almost all of it is metabolized in the liver. The main product, 5'-carboxy meloxicam (60% of the dose), is formed through an intermediate, 5'-hydroxymethyl meloxicam. CYP2C9 has the main role in this pathway and CYP3A4 a minor one, and none of the metabolites is known to be active [2]. CPIC's summary puts CYP2C9's share of meloxicam metabolism at 40 to 60% [3].
How CYP2C9 affects meloxicam
CYP2C9 also clears warfarin, phenytoin and several other NSAIDs. CPIC sorts its common alleles by function: *1 is normal function; *2, *5, *8 and *11 have decreased function; *3, *6 and *13 have no function. The two activity values a person inherits (1, 0.5 or 0 each) add up to an activity score from 0 to 2 [1].
| Activity score | Example genotypes | Phenotype |
|---|---|---|
| 2 | *1/*1 | Normal metabolizer |
| 1.5 | *1/*2 | Intermediate metabolizer |
| 1 | *1/*3, *2/*2 | Intermediate metabolizer |
| 0 or 0.5 | *3/*3, *2/*3 | Poor metabolizer |
In CPIC's frequency table, about 14% of people of European ancestry have an activity score of 1 and about 2.6% are poor metabolizers. The shares are similar in Near Eastern populations, highest in Central and South Asian populations (about 18% and 3.8%), and lower in East Asian, Latino and African-ancestry groups [4]. The celecoxib page lists them by population.
What changes in the blood
CPIC's pooled analysis of four small studies found about 80% more meloxicam exposure with *1/*3 than with *1/*1 (ratio of means 1.82, 95% confidence interval 1.32 to 2.52) [1]. Two no-function alleles have a much larger effect. In a Korean study, three people with *3/*3 had eight times the exposure and one-ninth the clearance of people with *1/*1 after a single 15 mg dose, and blood tests showed a much stronger drug effect (inhibition of thromboxane B2 formation) [5]. From this, CPIC expects a poor metabolizer's meloxicam half-life to exceed 100 hours [1]. The *2 allele has a smaller effect: CPIC rates the evidence for a modest drop in clearance as weak, and *1/*2 appears to have little impact [3].
What higher levels mean for side effects
The link from higher levels to harm is inferred rather than measured. CPIC rates the evidence that *3 is associated with meloxicam toxicity as weak, based on a single study [3]. Its recommendations rest on the exposure data and on the observation that NSAID side effects mostly come from the drug's intended action on COX enzymes, so they become more likely as dose or exposure rises [1].
What the guidelines recommend
CPIC published its guideline for CYP2C9 and NSAIDs in 2020 [1]. It lists the meloxicam and CYP2C9 pair at level A [6], CPIC's highest level: genetic information should be used to change prescribing [7]. Because meloxicam's half-life (15 to 20 hours) is longer than that of celecoxib or ibuprofen, CPIC treats it more cautiously than the shorter-acting NSAIDs. Its suggested alternatives are NSAIDs that CYP2C9 does not mainly clear (aspirin, ketorolac, naproxen and sulindac) or a CYP2C9-cleared NSAID with a shorter half-life, such as celecoxib, flurbiprofen, ibuprofen or lornoxicam. The recommendation for normal metabolizers is rated strong; the others are rated moderate [1].
The FDA's Table of Pharmacogenetic Associations lists meloxicam in Section 1, for associations where the data support therapeutic management recommendations: in poor metabolizers or *3 carriers, CYP2C9 variation "results in higher systemic concentrations", and the table advises considering dose reductions in poor metabolizers and monitoring for adverse reactions [8]. That advice appears in Section 8.8 of the labels for the meloxicam injections Xifyrm and Qamzova and for Zynrelef [9] [10] [11]. The label for Symbravo, a meloxicam and rizatriptan tablet for migraine, goes further and says its use is not recommended in known or suspected poor metabolizers [12]. The label for generic meloxicam tablets describes CYP2C9's role in metabolism but gives no genotype-based advice [2]. CPIC describes its own advice as adding detail to the FDA's, which calls for a lower starting dose in poor metabolizers without saying how much lower [1].
| Result | What it means | Guideline recommendation |
|---|---|---|
| Normal Metabolizer (activity score 2) | Normal meloxicam metabolism. | CPIC: the recommended starting dose, and the lowest effective dose for the shortest time that meets treatment goals, as the label advises. Rated strong. |
| Intermediate Metabolizer (activity score 1.5) | Mildly reduced metabolism. | CPIC: as for normal metabolizers. Rated moderate. |
| Intermediate Metabolizer (activity score 1) | Moderately reduced metabolism. Higher blood levels may make side effects more likely. | CPIC: 50% of the lowest recommended starting dose, increased with caution toward the desired effect or up to 50% of the maximum dose, and not before steady state (at least 7 days), with careful monitoring of blood pressure and kidney function. Alternatively, a drug not cleared by CYP2C9 or not meaningfully affected by its variants, or a CYP2C9-cleared NSAID with a shorter half-life. Rated moderate. |
| Poor Metabolizer (activity score 0 or 0.5) | Significantly reduced metabolism and a much longer half-life. Higher blood levels may make side effects more likely or more severe. | CPIC: a drug not cleared by CYP2C9 or not meaningfully affected by its variants, or a CYP2C9-cleared NSAID with a shorter half-life. Rated moderate. FDA: higher drug levels; consider a dose reduction and monitor for adverse reactions. |
| Indeterminate | An allele was found whose function is uncertain or unknown, so no phenotype can be assigned (CPIC's examples include *1/*7 and *1/*10). | CPIC: no recommendation. The report shows standard dosing (the recommended starting dose), the same advice as without a genetic result. |
Your Gene2Rx report shows the CPIC recommendation for your result alongside the FDA text, which covers poor metabolizers only.
Want to know what your genetics say about how you'll respond to Meloxicam?
A Gene2Rx report reads your own DNA to show how it may affect your response to Meloxicam and your other medications.
Using your result
Show your prescriber the full CYP2C9 result: the genotype (for example *1/*3), the activity score and the phenotype. CPIC advises recording the genotype because laboratories assign phenotypes in different ways [1]. Do not start, stop or change the dose of meloxicam because of a genetic result without your prescriber.
Other medicines that change CYP2C9 activity
A medicine that blocks CYP2C9 can make a normal metabolizer handle meloxicam more like an intermediate or poor metabolizer, an effect called phenoconversion. The Symbravo label warns that CYP2C9 inhibitors such as amiodarone and fluconazole may lead to abnormally high meloxicam levels [12]. The FDA also lists miconazole as a moderate CYP2C9 inhibitor, and rifampin and enzalutamide as moderate inducers, which speed the enzyme up [13].
If you take warfarin, CYP2C9 matters twice: people with decreased-function alleles who combine warfarin with an NSAID are more likely to have an INR (the clotting test used to adjust warfarin) above range or a major bleed, and CPIC recommends avoiding the combination in intermediate and poor metabolizers [1]. Adding another NSAID, including over-the-counter ibuprofen, raises the risk of stomach and bowel problems with little or no added benefit. The label lists aspirin, anticoagulants, oral corticosteroids, SSRI antidepressants, smoking, alcohol and older age as other risk factors for bleeding [2].
Other things that change the picture
The label does not recommend meloxicam in severe kidney impairment and caps the dose at 7.5 mg a day for people on hemodialysis. For older adults it advises starting at the low end of the dose range [2]. Whatever the CYP2C9 result, CPIC advises avoiding NSAIDs in people with kidney dysfunction or heart failure and in those at high risk of cardiovascular or gastrointestinal side effects [1].
Most people have an activity score of 2 or 1.5 [4], and for them CPIC's advice matches the label. A normal result does not make meloxicam risk-free: the label's boxed warning about heart attack, stroke and gastrointestinal bleeding applies to everyone who takes it [2].
What this result cannot tell you
Gene2Rx reads the variant calls in the file you upload. Consumer arrays from 23andMe, AncestryDNA and MyHeritage are not clinical-grade tests, and their raw data is labeled not for medical use. Arrays read fixed positions, and array processing uses imputation to infer some variants that were not measured directly. The report is built from the positions in your file or inferred by imputation, so a normal result means that none of the assessed variants was found among the positions your data covers. It cannot rule out a variant at a position the data does not cover, and CPIC warns that a person with such a rare variant can be assigned *1 and reported as a normal metabolizer [1]. This matters most for people of African ancestry, in whom *5, *6, *8 and *11 are more common than in other groups [4].
CPIC calls CYP2C9 one factor among many, alongside age, sex, liver function, other illnesses and other medicines [1]. CPIC defines no rapid or ultrarapid CYP2C9 group, so the gene does not explain meloxicam working poorly. Nor does it predict allergic reactions or aspirin-sensitive asthma, which rules out meloxicam [2]. CPIC notes that there is little prospective evidence that genotype-guided NSAID prescribing improves outcomes [1]. If your result says poor metabolizer and you take meloxicam long term, your prescriber may want to confirm it with a clinical CYP2C9 test.
Common questions
My meloxicam label does not mention poor metabolizers. Why?
The label for standard generic tablets describes CYP2C9 only in its metabolism section. The poor-metabolizer advice comes from CPIC, the FDA's table and the labels of other meloxicam products, as described in What the guidelines recommend.
I am an intermediate metabolizer. Do I need to stop meloxicam?
Not necessarily. At an activity score of 1.5, CPIC advises the usual dose. At 1, it advises a lower starting dose or another drug. The guidance table has the details to discuss with your prescriber.
Sources and further reading
- Theken KN et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs. Clin Pharmacol Ther (2020). Phenotypes, the meloxicam meta-analysis and the dosing recommendations.
- Meloxicam tablets, prescribing information. Cipla USA. DailyMed. Uses, doses, pharmacokinetics, metabolism and warnings.
- CPIC guideline for CYP2C9 and NSAIDs: supplement (2020). Evidence grades for meloxicam (Table S5) and pharmacokinetics (Table S12).
- CPIC. CYP2C9 frequency table (spreadsheet). Allele and activity score frequencies by population group.
- Lee HI et al. Strongly increased exposure of meloxicam in CYP2C9*3/*3 individuals. Pharmacogenet Genomics (2014). Meloxicam exposure and effect in *3/*3.
- CPIC. Gene-drug pairs and CPIC levels (ClinPGx). Level A for meloxicam and CYP2C9.
- CPIC. CPIC prioritization (ClinPGx). Definitions of the CPIC levels.
- FDA. Table of Pharmacogenetic Associations. Meloxicam and CYP2C9 in Section 1.
- Xifyrm (meloxicam) injection, prescribing information. Azurity Pharmaceuticals. DailyMed. Poor-metabolizer advice (Section 8.8).
- Qamzova (meloxicam) injection, prescribing information. DailyMed. Poor-metabolizer advice (Section 8.8).
- Zynrelef (bupivacaine and meloxicam), prescribing information. Heron Therapeutics. DailyMed. Poor-metabolizer advice (Section 8.8).
- Symbravo (meloxicam and rizatriptan) tablets, prescribing information. Axsome Therapeutics. DailyMed. Poor-metabolizer advice (Section 8.8) and CYP2C9 inhibitors (Section 7).
- FDA. For healthcare professionals: FDA's examples of drugs that interact with CYP enzymes and transporter systems. CYP2C9 inhibitors and inducers.
Genes that affect Meloxicam
See the full list of drugs affected by each gene:
Brand names containing Meloxicam
See how your genetics affect each product Meloxicam shows up in:
Meloxicam is also in 2 combination products, such as Zynrelef, Symbravo. Guidance is written for meloxicam on its own, so what your genes mean for a combination is less clear. See them all and how we handle combination products.
Related guides
Learn more about how genetics may affect your response to Meloxicam and related medications:
Interested in learning more about how your genetics may affect your response to medication? Get started with Gene2Rx today.
I'm Interested